{"id":"NCT01216943","sponsor":"Allergan","briefTitle":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","officialTitle":"A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, and Are on Twice-daily 0.2% Brimonidine/0.5% Timolol Ophthalmic Solution (Dual Combination) Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2010-10-07","resultsPosted":"2013-09-19","lastUpdate":"2013-09-19"},"enrollment":126,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution","otherNames":[]}],"arms":[{"label":"Triple Combination Therapy","type":"EXPERIMENTAL"}],"summary":"This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular hypertension who have elevated intraocular pressure (IOP) on brimonidine/timolol ophthalmic solution.","primaryOutcome":{"measure":"Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Triple Combination Therapy","deltaMin":22.35,"sd":3.417}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":1,"countries":["India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":121},"commonTop":["Conjunctival Hyperaemia"]}}